ADC Therapeutics SA Operating Cash Flow
ADC Therapeutics SA (ADCT) reported Operating Cash Flow of -$41.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- ADC Therapeutics SA net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$11.81M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$29.71M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$31.12M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$29.63M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for fiscal 2025 was -$141.17M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for fiscal 2024 was -$123.83M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for fiscal 2023 was -$118.69M.
- ADC Therapeutics SA net cash provided by (used in) operating activities for fiscal 2022 was -$138.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$41.52M 10-Q · filed 2026-08-13 | -$72.64M derived: sum of 3 quarters · filed 2026-08-13 | -$102.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$29.71M 10-Q · filed 2026-05-04 | -$60.83M derived: sum of 2 quarters · filed 2026-05-04 | -$90.46M derived: sum of 3 quarters · filed 2026-05-04 | -$114.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$31.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$60.75M derived: sum of 2 quarters · filed 2026-03-10 | -$84.84M derived: sum of 3 quarters · filed 2026-08-13 | -$141.17M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$29.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$53.72M derived: sum of 2 quarters · filed 2026-08-13 | -$110.05M 10-Q · filed 2025-11-10 | -$131.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$24.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$80.42M 10-Q · filed 2026-08-13 | -$102.27M derived: sum of 3 quarters · filed 2026-08-13 | -$127.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$56.33M 10-Q · filed 2026-05-04 | -$78.19M derived: sum of 2 quarters · filed 2026-05-04 | -$103.23M derived: sum of 3 quarters · filed 2026-05-04 | -$136.07M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$21.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$46.90M derived: sum of 2 quarters · filed 2026-03-10 | -$79.74M derived: sum of 3 quarters · filed 2026-03-10 | -$123.83M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$25.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$57.89M derived: sum of 2 quarters · filed 2025-11-10 | -$101.98M 10-Q · filed 2025-11-10 | -$133.62M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$32.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$76.94M 10-Q · filed 2025-08-12 | -$108.57M derived: sum of 3 quarters · filed 2025-08-12 | -$145.25M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$44.09M 10-Q · filed 2025-05-14 | -$75.73M derived: sum of 2 quarters · filed 2025-05-14 | -$112.40M derived: sum of 3 quarters · filed 2025-05-14 | -$147.39M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$31.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$68.31M derived: sum of 2 quarters · filed 2025-03-27 | -$103.29M derived: sum of 3 quarters · filed 2025-03-27 | -$118.69M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$36.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$71.66M derived: sum of 2 quarters · filed 2024-11-07 | -$87.05M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$34.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$50.38M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$15.39M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$138.31M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |